CVS Sheds Low-Performing Assets, Raises Profit Outlook
- CVS Health's Q3 2025 earnings ($1.60/share) and $102.9B revenue exceeded forecasts by $0.24/share and $4.07B, prompting third consecutive guidance hikes to $6.55-$6.65 adjusted EPS. - Aetna's improved medical benefit ratio (92.8% vs 95.2%) and Rite Aid pharmacy integration drove 11.7% segment growth, while Oak Street Health's $5.7B impairment led to 16 clinic closures by 2026. - Despite goodwill charges, $7.2B year-to-date operating cash flow reinforced resilience, with shares up 30% since CEO Joyner's 2
CVS Health Corp. (CVS) delivered third-quarter 2025 results that beat Wall Street forecasts, fueled by robust growth in its insurance and pharmacy divisions, and increased its annual earnings outlook for the third straight quarter. The company reported non-GAAP earnings per share (EPS) of $1.60, topping projections by $0.24, while revenue climbed 7.8% year-over-year to $102.9 billion, exceeding expectations by $4.07 billion,
The stronger performance was largely due to a rebound in CVS’s Aetna insurance business, which saw its medical benefit ratio drop to 92.8% from 95.2% a year earlier, indicating improved cost controls and more favorable premium reserves,
On the downside, CVS took a $5.7 billion goodwill impairment charge tied to its Oak Street Health primary care clinics, which it now plans to scale back. Joyner announced that 16 clinics will close by February 2026, with no additional clinics opening that year, as the division failed to meet expectations, Bloomberg reported. Nevertheless,
Shares initially slipped 1.5% in premarket trading after the earnings announcement, but the longer-term outlook remains optimistic. Analysts have raised their ratings, with a consensus "Outperform" recommendation, and CVS stock has gained nearly 30% since Joyner became CEO in 2024, Bloomberg reported. The updated guidance and improved operational efficiency have further bolstered investor sentiment, with the price-to-earnings ratio rising to 12 from 11 in the previous quarter, Finimize noted.
CVS’s results highlight its strategic pivot toward higher-margin insurance and pharmacy operations while shedding less profitable businesses. By emphasizing cost management and integrating Rite Aid’s assets, the company is working to strengthen its leadership in the changing healthcare sector.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ethereum News Update: ZKP’s Hardware-Centric Strategy Shakes Up Speculation-Fueled Crypto Presales
- ZKP launches with $17M pre-built Proof Pods, offering instant AI compute rewards via Wi-Fi-connected hardware. - Unlike speculative presales, ZKP's hardware-first model ensures operational readiness and decentralized network resilience. - Competitors like Blazpay and SpacePay focus on utility-driven crypto adoption, but ZKP's tiered, upgradable devices emphasize verifiable performance. - Ethereum's gas limit increase aligns with ZKP's distributed compute approach, addressing scalability challenges throug
Solana News Update: Investors Shift Toward XRP ETFs, Bringing Solana's 21-Day Inflow Streak to a Close
- Solana ETFs ended a 21-day inflow streak with a $8.1M net outflow on Nov 27, 2025, led by 21Shares TSOL's $34.37M redemptions. - This reversal contrasted with Bitcoin/Ethereum ETFs' $5.43B outflows and highlighted Solana's 7% staking yields and 70M daily transactions. - Analysts linked the shift to profit-taking, macroeconomic pressures, and investor rotation toward XRP ETFs with perfect inflow records. - Despite the outflow, Solana ETFs still hold $964M in assets, but face challenges as TVL dropped 32%
XRP News Today: Institutional ETFs Drive XRP to Compete with Bitcoin's Market Leadership
- XRP ETFs see $160M+ inflows as institutional demand surges, with Bitwise and Franklin Templeton leading the charge. - NYSE approves Grayscale and Franklin XRP/Dogecoin ETFs amid SEC easing altcoin fund approvals, signaling crypto normalization. - Altcoin Season Index at 25/100 shows Bitcoin dominance, but projects like Aster and Zcash outperform BTC by 1,000%+. - XRP rebounds to $2.06 with 48% volume spike, but 79M tokens absorbed by ETFs raise supply concerns. - Institutional-grade custody solutions fro
Public-Private Collaborations Driving Real Estate and Industrial Expansion in Webster, NY
- Webster , NY, leverages PPPs via FAST NY and NY Forward grants to boost infrastructure, real estate , and industrial investment. - Xerox campus upgrades and downtown revitalization projects enhance connectivity, attracting advanced manufacturing and logistics sectors. - $650M fairlife® facility creates 250 jobs, demonstrating how modernized infrastructure attracts high-value industries to secondary markets. - Websters model shows PPPs can drive sustainable growth by aligning public funding with private-s
Trending news
MoreCrypto prices
More
